1Karkouti K, Wijeysundera DN, Yau TM, et al. The independent as- sociation of massive blood loss with mortality in cardiac surgery[J]. Transfusion, 2004, 44:1453-1462.
2Lee AI, Campigotto F, Rawn JD, et al. Clinical significance of coag- ulation studies in predicting response to activated recombinant Fac- tor VI in cardiac surgery patients[J]. Br J Haemotol, 2012, 157:397- 400.
3Elizalde M, Slobodskoy L, Diodato M, et al. Use of Recombinant Factor VII in cardiac surgery[J]. Recent Pat Cardiovasc Drug Dis- cov, 2012, 7:216-220.
4Hedner U, lnqerslev J. Clinical use of recombinant F VI a(rF VII a)[J]. Transfus Sci, 1998, 19:163-176.
5Lodge JP, Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor Vla in liver transplantation [J]. Liver Transpl, 2005, 11:973-979.
6Kenet G, Walden R, Eldad A, et al. Treatment of traumatic bleeding with recombinant factor Vlla[J]. Lancet, 1999, 354:1879.
7Phillip LE, McLintock C, Pollock W, et al. Recombinant activated factor W in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry[J]. Anesth Analg, 2009, 109: 1908-1915.
8O' Connell KA, Wood J J, Wise RP, et ah Thromboembolie adverse events after use of recombinant human coagulation factor Wl a[J]. JAMA, 2006, 295:293-298.
9A1-Ruzzeh S, Navia JL. The "off-label" role of recombinant factor V in surgery: is the problem deficient evidence or defective con- cept?[J]. J Am Coil Surg, 2009, 209:659-667.
10Uber WE, Toole JM, Strand MR, et al. Administration of recombi- nant activated factor VII in the intensive care unit after complex car- diovascular surgery: clinical and economic outcomes[J]. J Thorac Cardiovasc Surg, 2011,141:1469-1477.
